Goldline Pharmaceutical Share Price
03 Aug, 2026 1:35 PM (IST)
Goldline Pharmaceutical Performance
- Today's Low
- ₹41
- Today's High
- ₹41
- 52 Week Low
- ₹33
- 52 Week High
- ₹60
- Open Price₹41
- Previous Close₹41
- Volume3,000
- 50 DMA₹43.60
- 100 DMA-
- 200 DMA-
Goldline Pharmaceutical Chart
Investment Returns
- Over 1 Month -2.44%
Smart Investing Starts Here Start SIP with Goldline Pharmaceutical for Steady Growth!
Goldline Pharmaceutical Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 9.6
- PEG Ratio
- -
- Market Cap Cr
- 40
- P/B Ratio
- 3
- Average True Range
- 2.1
- EPS
- 4.3
- Dividend Yield
- 0
- MACD Signal
- -1.2
- RSI
- 47.98
- MFI
- 22.83
Latest Stock News Updates
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prashant Shrikrishna Karkare
- BSE India
- 4 days 5 hours ago
Appointment of M/s. Avinash Prakash Gandhewar, Practicing Company Secretaries, Membership No. FCS 11197 as Secretarial Auditor of the Company for the FY 2025-26.
- BSE India
- 2 weeks 5 days ago
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyGoldline Pharmaceutical Ltd 2CIN NO.U51397MH2004PLC147806 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 9.16 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: RUCHI SANKET MODI Designation: COMPANY SECRETARY EmailId: GOLDLINEPHARMACEUTICALSLTD@GMAIL.COM Name of the Chief Financial Officer: DIPTI SHARAD BHUSARI Designation: CHIEF FINANCIAL OFFICER EmailId: GOLDLINEPHARMACEUTICALSLTD@GMAIL.COM Date: 24/06/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
- BSE India
- 1 month 1 week ago
Goldline Pharmaceutical Financials
Goldline Pharmaceutical Technicals
EMA & SMA
- Bearish Moving Average 3
- Bullish Moving Average 8
- 20 Day
- ₹40.60
- 50 Day
- ₹43.60
- 100 Day
- -
- 200 Day
- -
Resistance and Support
- R3 43.70
- R2 42.70
- R1 42.00
- S1 40.30
- S2 39.40
- S3 38.60
Goldline Pharmaceutical Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-06-09 | Audited Results |
About Goldline Pharmaceutical
Goldline Pharmaceutical are engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” View More- NSE Symbol
- GLPL
- BSE Symbol
- 544759
- ISIN
- INE1CLW01015
Similar Stocks to Goldline Pharmaceutical
Popular Stocks
Goldline Pharmaceutical FAQs
Goldline Pharmaceutical share price is ₹41 As on 03 August, 2026 | 13:30
The Market Cap of Goldline Pharmaceutical is ₹39.6 Cr As on 03 August, 2026 | 13:30
The P/E ratio of Goldline Pharmaceutical is 9.6 As on 03 August, 2026 | 13:30
The PB ratio of Goldline Pharmaceutical is 3 As on 03 August, 2026 | 13:30
The 52 week High & Low of Goldline Pharmaceutical is ₹60/₹33 respectively As on 03 August, 2026 | 13:30
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.